Vol. 1 No. 11 (2021)
Reimbursement Reviews

Larotrectinib (Vitrakvi)

Published November 12, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses larotrectinib (Vitrakvi); 25 mg and 100 mg capsules (as larotrectinib sulphate) and 20 mg/mL oral solution (as larotrectinib sulphate).
  • Indication: For the treatment of adult and pediatric patients with solid tumours that:
    • have an NTRK gene fusion without a known acquired resistance mutation
    • are metastatic or where surgical resection is likely to result in severe morbidity
    • have no satisfactory treatment options.